<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03290053</url>
  </required_header>
  <id_info>
    <org_study_id>CE-5S</org_study_id>
    <nct_id>NCT03290053</nct_id>
  </id_info>
  <brief_title>Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)</brief_title>
  <acronym>CE-5S</acronym>
  <official_title>Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute ischemic stroke in anterior circulation within 4,5 hours of symptom
      onset, has a bone window and Trombolysis In Brain Ischemia (TIBI) &lt;=4 in a relevant artery
      eligible. Both patients receiving thrombolysis and those who do not due to contraindications
      such as anticoagulation or recent surgery are enrolled, but into different study arms (CE-5S
      A for thrombolysis and B for non-thrombolysis); the decision to treat with thrombolysis or
      not is done according to clinical routine.

      All included patients are randomized to receive transcranial ultrasound and SonoVue-infusion
      or sham-ultrasound and placebo; i.e. in CE-5S A, contrast enhanced sonothrombolysis is
      compared to thrombolysis and in CE-5S B, contrast enhanced sonolysis is compared with
      conservative management.

      Main outcome is improvement in National Institute of Health Stroke Scale (NIHSS) at 24 hours
      compared to baseline. Main safety outcome is symptomatic intracerebral haemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor inclusion rate &amp; lack of funding
  </why_stopped>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">April 18, 2018</completion_date>
  <primary_completion_date type="Actual">April 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early clinical Outcome defined as change in NIHSS at 24 hours.</measure>
    <time_frame>24 hours</time_frame>
    <description>Change in National NIHSS at 24 hours. Defined reaching of primary endpoint is post-treatment 0 Points and/or improves with &gt;=4 Points compared to pre-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Symptomatic Cerebral Hemorrhage (sICH)</measure>
    <time_frame>24-36 hours</time_frame>
    <description>Assessed with routine post-treatment CT head and requires an accompanied &gt;=4 Points worsening on NIHSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term outcome defined as residual handicap at Three months</measure>
    <time_frame>90 days</time_frame>
    <description>90-days modified Rankin Scale (mRS) reaching 0-1.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>CE-5S A: Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gets thrombolysis, transcranial ultrasound on the flow limitation and SonoVue infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CE-5S A: Control arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Gets thrombolysis, sham transcranial ultrasound and placebo (NaCl) infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CE-5S B: Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gets NO thrombolysis (due to contraindications), transcranial ultrasound on the flow limitation and SonoVue infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CE-5S B: Control arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Gets NO thrombolysis (due to contraindications), sham transcranial ultrasound and placebo (NaCl) infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SonoVue</intervention_name>
    <description>SonoVue-infusion over 1 hour</description>
    <arm_group_label>CE-5S A: Treatment arm</arm_group_label>
    <arm_group_label>CE-5S B: Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <description>Placebo</description>
    <arm_group_label>CE-5S A: Control arm</arm_group_label>
    <arm_group_label>CE-5S B: Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcranial Ultrasound</intervention_name>
    <description>Transcranial ultrasound aimed at the blockage</description>
    <arm_group_label>CE-5S A: Treatment arm</arm_group_label>
    <arm_group_label>CE-5S B: Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Transcranial Ultrasound</intervention_name>
    <description>Placebo - machine is attached, but not active</description>
    <arm_group_label>CE-5S A: Control arm</arm_group_label>
    <arm_group_label>CE-5S B: Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients ≥18 years with acute ischaemic stroke in the anterior
             circulation, who has given written consent for his/her participation to the study.

          -  Remaining neurological deficit that is ≥1 NIHSS points, sufficient to warrant
             treatment with tPA (not taking possible contraindications into account) and is severe
             enough that possible improvement is clearly analysable

          -  Treatment &lt;4½ hours of symptom onset or of waking up in the morning with symptoms

          -  Sufficient bone window for acceptable or better acquisition of flow information with
             ultrasound with TIBI ≤ 4 in the symptomatic artery

          -  In cases with women of Childbearing Capacity (WOCBC): Only if willing to comply with
             effective contraception methods during the course of the trial. Acceptable methods are
             such as oral contraceptives, contraceptive patches, contraceptive implant, vaginal
             contraceptive, double-barrier methods (for example, condom and spermicide),
             intrauterine device (IUD), hormonal IUD

        Exclusion Criteria:

          -  Patients with premorbid modified Rankin Scale (mRS) score ≥3;

          -  Patients for whom a complete NIHSS cannot be obtained;

          -  Hemiplegic migraine with no arterial occlusion on baseline Computed Tomography of
             brain (CT);

          -  Seizure at stroke onset and no visible occlusion on baseline CT;

          -  Intracranial haemorrhage on baseline CT;

          -  Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is
             normal;

          -  Large areas of hypodense ischaemic changes on baseline CT;

          -  Pregnancy or breast-feeding, pericarditis; sepsis; any other serious medical illness
             likely to interact with treatment; confounding pre-existent neurological or
             psychiatric disease; unlikely to complete follow-up; any investigational drug &lt;14
             days;

          -  Inability to provide informed consent sufficiently clearly that the study physician
             can be convinced that informed consent has been given by the patient - such as severe
             aphasia or coma.

        Specific sonothrombolysis exclusion criteria

          -  known hypersensitivity/allergy to SonoVue;

          -  recent or unstable coronary ischemia or resting angina &lt;7 days;

          -  acute cardiac insufficiency, cardiac insufficiency class III/IV; serious cardiac
             arrhythmias;

          -  any right-left-shunt; severe pulmonary hypertension; uncontrolled hypertension;

          -  moderate to severe Chronic Obstructive Pulmonary Disease (COPD; baseline O2 saturation
             &lt;80%);

          -  acute respiratory distress syndrome (ARDS);
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Johansson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Umeå</city>
        <state>Västerbotten</state>
        <zip>90821</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

